Llwytho...

Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAF(V600)-Mutated Nonmelanoma Tumors

BRAF(V600) mutations occur in multiple nonmelanoma tumors, but no US Food and Drug Administration–approved BRAF-targeted therapies exist for these cancers. BRAF inhibitor vemurafenib was recently found to demonstrate activity across various BRAF-mutated nonmelanoma cancer types. However, most tumors...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Natl Cancer Inst
Prif Awduron: Sen, Shiraj, Meric-Bernstam, Funda, Hong, David S., Hess, Kenneth R., Subbiah, Vivek
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2017
Pynciau:
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6059192/
https://ncbi.nlm.nih.gov/pubmed/29117359
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djx094
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!